Login
Open Demat Account
Open Demat A/C
Offerings
+
Research
Markets+
Talking Finance+
Support+
Media+
Partner Us+
Trade LoginReports LoginIFD Partner Login
Demo
Close Language Tab
Locate us
Languages
  • Home
  • Company Information
  • Lupin Ltd
L
Lupin Ltd Pharmaceuticals
₹ 1,984.60 0.00 (0.00%)
  • NSE
  • BSE

Overview

  • BSE Code 500257
  • NSE Symbol LUPIN
  • ISIN Demat INE326A01037
  • Book Value (₹) 531.58
  • Face Value (₹) 2.00
  • Market Cap (₹ Cr.) 88,185.03
  • P/E (TTM) 21.85
  • EPS (TTM) 88.38
  • Div Yield (%) 0.62

Performance

Today’s Low 1,940.00
Today’s High 1,992.10

1,984.60
52W Low 1,795.20
52W High 2,402.90

1,984.60
Open 1,986.00
Prev. Close 1,984.60
Volume 9,07,495.00

Corporate Actions

Lupin Limited - ESOP/ESOS/ESPS
Apr 28, 2025

Lupin Limited has informed the Exchange regarding Allotment of 51495 Shares.

Lupin Limited - Alteration Of Capital and Fund Raising-XBRL
Apr 28, 2025

LUPIN LIMITED has informed the Exchange regarding Allotment of Securities

About Lupin Ltd

Lupin Ltd is involved in the business of manufacturing pharmaceuticals. The company originated as in 1968. Lupin Laboratories Pvt. Ltd. came into existence as in 1972. It commissioned the first formulations plant and R&D Centre at Aurangabad in 1979. Lupin received US FDA approvals for the Ankleshwar and Mandideep plants in 1989. The company was listed on an exchange in 1993 after an IPO. In 2000, the company received US FDA approval for the Cefotaxime facility at Mandideep. Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd., and as a result, Lupin Ltd was formed in 2001. After 2 years (2003), it incorporated Lupin Pharmaceuticals Inc. USA for trading, marketing and developmental activities in the US. In 2007, the company gained complete control of Rubamin Laboratories Ltd., Vadodara and renamed it Novodigm Ltd. It became the 5th largest generic player in the US in 2010. Post 2 years, the company made a strategic entry into the NIFTY 50 Index in 2012. The company finished the acquisition of Symbiomix Therapeutics, LLC, New Jersey, U.S., in 2017. It launched Atharv Ability – State-of-the-Art, Multi-Disciplinary Neuro Rehabilitation Center in Mumbai in 2023. Lupin’s Supply Chain Team won the award for ‘Best-in-Class Supply Chain Strategy’ at the 15th ELSC Leadership Awards in 2023.

Business Segments

  • Key Therapeutic Areas:The company delivers an expansive portfolio of products under this segment. Through this segment, it enjoys a  substantial market share in therapies such as cardiovascular, respiratory, diabetes, neurology, gastrointestinal and women’s health.
  • Generics:The organization’s generic enterprise is ranked #6 in the Indian Pharmaceutical Market (IPM). It possesses a significant presence in CNS, gynaecology, pain management and vitamin-mineral supplements, among others.
  • Biosimilars:The organization administers this segment through Lupin Biotech, which manufactures high-quality biologics that are accessible and affordable for patients globally. Products under this segment include Filgrastim and Peg-Filgrastim, and Etanercept.
  • Specialty: The specialty enterprise of the organization is supported by strong research and manufacturing capabilities. The specialty products under this segment include Solosec in the US and NaMuscla in Europe.
  • Over-the-Counter (OTC):Under this segment, the organization produces drugs, which are considered the first line of defence against non-serious ailments. A few of the products under this segment include LupinLife, Softovac, Lupizyme, etc.
  • Active Pharmaceutical Ingredients (API):The company is one of the foremost API manufacturer in India. It supplies to more than 70 countries around the globe.
  • Global Institutional Business (GIB):This segment offers high-quality, affordable, and reliable medicines to underserved communities, enabling a healthy and disease-free life. The company has evolved into a comprehensive solution for all anti-TB medications.
  • Tech-Driven Offerings:The company offers tech-enabled products such as Bluetooth-enabled inhalation devices or an AI-driven chatbot to answer queries about key therapies.

Subsidiary

As of March 31, 2023, the company had 28 subsidiaries and a few of them are listed below:
  • Lupin Pharmaceuticals, Inc., USA:It is a wholly owned subsidiary of Lupin Ltd, which came into existence as on June 30, 2003. It manufactures, markets and/or distributes more than 181 drugs in the United States.
  • Pharma Dynamics (Proprietary) Limited, South Africa:This is a wholly-owned subsidiary of the organization, which is one of the largest generic medicine providers in South Africa.

Key Personnel

Nilesh D Gupta, Managing Director Nilesh D Gupta is currently the MD of Lupin. He was inducted into the company in 2002 and is responsible for its research, supply chain, manufacturing, quality, and regulatory operations. Mr Gupta has been involved in developing and executing the company’s core strategy, which has helped it emerge as a global leader in the generics space and in India.

Management Outlook

  • The organization believes that its India enterprise has a very positive outlook and is well poised to achieve sustainable growth. Lupin is actively working on various initiatives to enhance its performance, which include core prioritying on enterprise imperatives, process improvement, and engaging with stakeholders such as doctors, patients, distribution channels, and consumers.
  • The organization is in a decent position to achieve new milestones and contribute to a brighter future by leveraging its brand-building capabilities, enhanced manpower and robust portfolio of products and by targeting depth into specific therapeutic segments.
Founded: 1983
Chairman: M D Gupta
Managing Director: Nilesh Deshbandhu Gupta.
Address: Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055,